Here are the latest cancer drugs approved by the Food and Drug Administration:

  • Breyanzi (lisocabtagene maraleucel) CAR-T therapy for large B-cell lymphoma
  • Danyelza (naxitamab) for neuroblastoma in the bones
  • Margenza (margetuximab) for HER2-positive breast cancer
  • Orgovyx (relugolix) for prostate cancer
  • Tepmetko (tepotinib) for non-small-cell lung cancer
  • Ukoniq (umbralisib) for marginal zone and follicular lymphoma